🟢 Biovie is trading 5% up in pre-market

Biovie is trading at $1.40, up 5.26%, with no confirmed catalyst identified for the pre-market move.

• An October 26 announcement said BioVie was invited to present bezisterim Long COVID data at the NIH's RECOVER-TLC Third Annual Workshop; available reporting does not connect it to the share-price change.
• The supplied market context shows modest index gains, not a clear broad-market explanation.
• Pre-market volume was unavailable in the sources reviewed.